News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News
Gilead Sciences

Gilead's Descovy approved in HIV prophylaxis

The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of cutting the risk of sexually acquired infection with an improved safety profile compa

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

News
Windward Bio catches $175m from its IPO

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

Partner Content

Partner Content
LEAP HR: Life Sciences Europe
Partner Content

LEAP HR: Life Sciences Europe

Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences